文献速递生殖医学

虚拟现实在子宫输卵管造影(HSG)中未能缓解疼痛:一项随机对照试验结果

No pain relief by virtual reality during hysterosalpingography (HSG): results from a randomized controlled trial.
PubMed 文献 · Hum Reprod · 2024-01-01

这项两中心、开放标签随机对照试验于2021年1月至2022年10月纳入134例行子宫输卵管造影(HSG)的不孕症女性,比较佩戴虚拟现实(VR)头戴设备与不佩戴的疼痛评分。结果显示,VR组与对照组的峰值疼痛和总体疼痛视觉模拟评分(VAS)均无显著差异;校正对VR的期望后,VR组疼痛评分反而显著更高。作者结论认为HSG过程中不应使用VR作为额外工具。

要点

  • VR组峰值疼痛VAS均值为6.80 cm,对照组为6.60 cm,差异无统计学意义(P=0.52)。
  • VR组总体疼痛VAS均值为5.00 cm,对照组为4.90 cm,差异无统计学意义(P=0.88)。
  • 校正对VR的期望后,VR组峰值和总体疼痛评分均显著高于对照组。

核心结论

  • 与不佩戴VR的HSG相比,佩戴VR的HSG并未降低操作过程中的疼痛评分。
  • 校正对VR的期望后,VR组报告的峰值疼痛和总体疼痛评分均显著高于对照组。
  • 由于VR不能减轻操作疼痛,作者认为HSG过程中不应使用这一额外工具。

研究设计与样本

  • 研究类型为两中心、开放标签随机对照试验。
  • 研究于2021年1月至2022年10月进行,纳入因不孕症检查而预约HSG的女性。
  • 共纳入134名女性,VR组69例,对照组65例;因干预性质研究未设盲。
  • VR通过头戴设备实施,显示自然影片和/或放松练习。
  • 主要终点为HSG后立即测量的操作疼痛VAS评分(0.0-10.0 cm),分为总体疼痛和峰值疼痛。

主要发现

  • 峰值疼痛VAS均值:VR组6.80 cm(SD 2.25)vs 对照组6.60 cm(SD 2.40),均值差0.28(95%CI -0.57, 1.12),P=0.52。
  • 总体疼痛VAS均值:VR组5.00 cm(SD 2.10)vs 对照组4.90 cm(SD 2.13),均值差0.06(95%CI -0.71, 0.84),P=0.88。
  • 对VR作为良好分散注意力的期望与总体和峰值疼痛评分均相关。
  • 校正该期望后,VR组峰值疼痛校正均值差0.58(95%CI -0.81, 1.97),P=0.021;总体疼痛校正均值差0.43(95%CI -0.84, 1.71),P=0.013,均显著高于对照组。
  • 被视为VR不良反应的症状发生率两组间无差异。

关键数值与推荐

  • 疼痛采用VAS评分(0.0-10.0 cm)测量,分为总体疼痛和峰值疼痛。

临床怎么用

  • 作者结论认为,由于VR不能减轻操作疼痛,HSG过程中不应使用这一额外工具。

局限性

  • 研究未设盲。
  • 拒绝参与研究的原因包括焦虑或希望在HSG过程中完全掌控,可能造成选择偏倚。
  • 分散注意力评分可能提示由于缺乏声音和/或VR应用类型,VR沉浸程度并非最佳。
  • 未来研究应探讨更具沉浸感或互动性的VR应用是否能降低HSG过程中的疼痛评分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is virtual reality (VR) an effective non-pharmacological tool to reduce procedural pain during hysterosalpingography (HSG)? SUMMARY ANSWER: An HSG with VR does not reduce procedural pain scores compared to an HSG without VR. WHAT IS KNOWN ALREADY: An HSG is often experienced as painful and uncomfortable. VR has been proven successful to reduce acute procedural pain during a variety of medical procedures and interventions. STUDY DESIGN, SIZE, DURATION: We performed a two-centre open-label randomized controlled trial between January 2021 and October 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women scheduled for HSG as part of their infertility work-up were screened for participation. After informed consent, women were randomized between HSG with or without VR. Due to the nature of the intervention, the study was not blinded. VR was administered by a head-mounted device displaying nature movies and/or relaxation exercises. The primary endpoint was procedural pain measured using VAS (scale 0.0-10.0 cm). Procedural pain was divided into overall pain score and peak pain score during the procedure. It was measured immediately after HSG. Secondary endpoints included patient satisfaction, VR preferences, and adverse effects of VR. MAIN RESULTS AND THE ROLE OF CHANCE: We included a total of 134 women, 69 to the intervention group (HSG with VR) and 65 to the control group (HSG without VR). The mean VAS for peak pain was 6.80 cm (SD 2.25) in the intervention group versus 6.60 cm (SD 2.40) in the control group (mean difference 0.28 (95% CI -0.57, 1.12), P = 0.52). The mean VAS for overall pain was 5.00 cm (SD 2.10) in the intervention group versus 4.90 cm (SD 2.13) in the control group (mean difference 0.06 (95% CI -0.71, 0.84), P = 0.88). The expectation that VR would be a good distraction from pain during HSG was correlated with both overall and peak pain scores. When correcting for this expectation, we found that women in the intervention group reported significantly higher scores, both in peak (adjusted MD 0.58 (95% CI -0.81, 1.97), P = 0.021) and overall (adjusted MD 0.43 (95% CI -0.84, 1.71), P = 0.013) pain, compared to the control group. There were no differences in the prevalence of symptoms that were considered as adverse effects of VR. LIMITATIONS, REASONS FOR CAUTION: The study was not blinded. Reasons for declining participation in the study were anxiety or wanting full control during HSG, which might have created selection bias. The distraction score possibly indicates that the level of VR immersiveness was not optimal due to the lack of sound and/or the type of VR applications. Future studies should investigate whether more immersive or interactive VR applications could decrease procedural pain scores during HSG. WIDER IMPLICATIONS OF THE FINDINGS: Since VR does not reduce procedural pain, this additional tool should not be used during HSG. STUDY FUNDING/COMPETING INTEREST(S): There was no external funding for this study. KR and AvH report receiving a travel grant from Merck outside the scope of this study. BM is supported by a National Health and Medical Research Council (NHMRC) investigator grant (GNT1176437) and BM reports consultancy for Merck, Organon, and Norgine and travel and research funding from Merck. BM holds stock for ObsEva. CL reports receiving research grants from Merck, and Ferring. KD and VM report receiving travel and speaker's fees from Guerbet and research grants from Guerbet. VM also reports research grants from Merck and Ferring. The remaining authors have nothing to declare. TRIAL REGISTRATION NUMBER: The trial is registered prospectively in the Netherlands Trial Register (trialregister.nl registration number NL9203, currently accessible on trialsearch.who.int). TRIAL REGISTRATION DATE: 16-01-2021. DATE OF FIRST PATIENT’S ENROLMENT: The first participant was enrolled on 19 January 2021.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Rosielle K, van Haaps AP, Kuijper EAM, et al. No pain relief by virtual reality during hysterosalpingography (HSG): results from a randomized controlled trial. Hum Reprod. 2024. PMID: 38863305. doi:10.1093/humrep/deae133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。